Company Description
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia.
It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates.
The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers; and acquires milestone and royalty revenue streams on late-stage clinical assets and commercial assets.
It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024.
XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
| Country | United States |
| Founded | 1981 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Owen Hughes |
Contact Details
Address: 2200 Powell Street, Suite 310 Emeryville, California 94608 United States | |
| Phone | 510 204 7200 |
| Website | xoma.com |
Stock Details
| Ticker Symbol | XOMA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000791908 |
| CUSIP Number | 98419J206 |
| ISIN Number | US98419J2069 |
| Employer ID | 52-2154066 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Owen P. Hughes Jr. | Chief Executive Officer and Director |
| Bradley Sitko | Chief Investment Officer |
| Jeffrey Trigilio | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 30, 2026 | ARS | Filing |
| Mar 30, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 30, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 27, 2026 | SCHEDULE 13G/A | Filing |
| Mar 18, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 18, 2026 | 10-K | Annual Report |
| Mar 18, 2026 | 8-K | Current Report |
| Mar 6, 2026 | SCHEDULE 13G/A | Filing |
| Mar 2, 2026 | 8-K | Current Report |
| Feb 12, 2026 | SCHEDULE 13G/A | Filing |